Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity

Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity in Normal Women With Cytology

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03895905

Enrollment

409

Registered

2019-03-29

Start date

2016-12-01

Completion date

2019-01-01

Last updated

2019-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Neoplasm, Human Papilloma Virus

Keywords

colposcopy, High Risk HPV

Brief summary

The only malignancy screening test among gynecological cancers is cervical cancer. Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program. Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year. the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them. In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.

Interventions

DIAGNOSTIC_TESTcolposcopy and colposcopic biopsy

high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 20-65 years old * patients with normal smear

Exclusion criteria

* Patients with invasive cervical cancer, * HIV-positive patients, * ASCUS and more risky premalignant lesions in cytology, * Over the age of 65 and * Patients under 20 years of age, * patients with another known gynecological malignancy

Design outcomes

Primary

Measure	Time frame	Description
Genotype of HR-HPV 16/18	1 MONTH	Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV 16/18
Genotype of HR-HPV non 16/18	1 MONTH	Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV non 16/18

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026